DiaMedica Therapeutics Inc.

Good morning, ladies and gentlemen, and welcome to the Diametica Therapeutics first quarter 2025 conference call. An audio recording of the webcast will be available shortly after the call today on Diametica's website at www.diametica.com in the investor relations section. Before Diametica proceeds with its remarks, please note that the company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results, appears in the section entitled Cautionary Note Regarding Forward-Looking Statements in the company's press release issued yesterday and under the heading Risk Factors in the company's most recent annual report on Form 10-K, and most recent quarterly report, Form 10-Q. Diametica's SEC filings are available on the SEC's website, www.sec.gov, and on its website, diametica.com. Please also note that any comments made on today's call speak only as of today, May 14, 2025, and may no longer be accurate at the time of any replay or transcript rereading. Diomedica disclaims any duty to update its forward-looking statements. Following the prepared remarks, the phone lines will be open for questions. I would now like to turn you over to your host for today's call, Mr. Rick Pauls, Diomedica's president and chief executive officer. Mr. Pauls?

Thank you, operator. Hello, everyone, and welcome to our first quarter 2025 conference call. I am joined this morning by Scott Kellan, our chief financial officer. Dr. Lorianne Masioka is currently on short-term medical leave, and we hope she gets well soon. We're happy to be here today to update you on the progress on our two clinical development programs. It has only been a short interval since our last update, thus I will keep my remarks brief. That said, I'm pleased to report that we continue to make substantial progress in both of our clinical development programs. I'll start with an update on our preeclampsia program. Building upon the significant accomplishments of this program within a very short timeframe, as we discussed in March, we're pleased to be able to disclose that we believe Part 1A of our Phase 2 investigator-sponsored preeclampsia trial is very close to identifying a target dose to move forward within in Part 1B. Dose selection will be guided primarily by a few key data points, which we expect to be sharing in our upcoming preliminary top-line results from the Part 1A proof-of-concept portion of the trial. These key data points include, one, safety and tolerability, including results of a placental transfer analysis, two, the amount of decrease in systolic and diastolic blood pressure levels, and three, changes in uterine and placental blood flow as assessed by the Doppler ultrasound measurement of the uterine artery pulsatility index. This measure is important as reductions in the Pulsatility Index may suggest decreased downstream resistance and improved uterine and placental blood flow, which could also be an indication of disease modifying. Currently, we expect to be in a position to release those preliminary topline results between the second half of June and the first half of July. The final timing will be primarily dependent on the schedules at the outside laboratories running the various tests, including the pharmacodynamic biomarkers, and the assay, which will be used to determine if DM1A9 crosses the placental barrier. One additional update, May is preeclampsia awareness month, and we will be sponsoring a preeclampsia key opinion leader call on May 28th at 8 a.m. Eastern. Compared to other therapeutic areas like oncology, which have advanced more rapidly in recent years, the treatment of pregnancy complications remains outdated and is not well understood. No FDA-approved treatments exist for preeclampsia despite the growing burden of this disease. To our knowledge, DM-109 is the only novel agent currently being studied in pregnant women with preeclampsia. With this KOL event, we will continue our work to educate investors, physicians, and other interested parties on preeclampsia as a disease and the current state of treatment. With this background, we will also discuss the design of our current Phase II trial of DM-199 in preeclampsia. Turning briefly to our stroke program, enrollment is moving ahead steadily and we're pleased to announce that participant enrollment now is between the 20th and 25th percentile mark of patients enrolled for the interim analysis. Our next enrollment update will be at the 50th percentile mark. We believe that our efforts over the past year to engage with sites, to promote communications between the sites, and to simplify study logistics have been important in driving the recent uptick in enrollment. Accordingly, we reiterated our guidance that the interim analysis on those first 200 participants will be completed in the first half of 2026. I would also note for you that we have engaged an experienced stroke neurologist to support site engagement during Lorianne's leave in order to maintain our enrollment momentum in the Remedy 2 trial. This individual has spent over 10 years treating stroke patients at a major U.S. research center and also has five years of recent biotech drug development experience. He has been doing a tremendous job connecting with and maintaining our relationships with sites and supporting our recent enrollment momentum. Now, I'd like to hand the call over to Scott Kellan to review this quarter's financial results.

Thanks, Rick, and good morning, everyone. As the operator mentioned, we announced our first quarter 2025 financial results and filed our quarterly report on Form 10-Q yesterday after the markets closed. These documents are both available on either the Diametica or the SEC websites. As of March 31, 2025, we reported a total combined cash and investments of $37.3 million, current liabilities of $4.7 million, and working capital of $32.8 million. This compares to a total combined cash and investments of $44.1 million, $5.4 million in current liabilities, and $39.2 million in working capital as of December 31, 2024. The decreases in combined cash and investments and in working capital were due primarily to the net cash used to fund our operations. The net cash used in operating activities for the first quarter of 2025 was $7.1 million compared to 6.7 million for the first quarter of 2024. The increase in cash used in operating activities resulted primarily from our increased net loss, partially offset by changes in operating assets abilities occurring during the current year period. We anticipate that our current cash and investments provides us a runway into Q3 of 2026. Our research and development expenses increased to $5.7 million for the three months ended March 31, 2025, up from $3.7 million for the three months ended March 31, 2024. The increase was due primarily to cost increases resulting from the continuation of our Remedy 2 clinical trial, including our global expansion, increased manufacturing development activity, and the expansion of our clinical team during 2024. Now, these increases were partially offset by cost reductions related to in-use study work performed and completed in the prior year period. We expect that our R&D expenses will moderately increase in future periods relative to our recent prior periods as we continue our Remedy 2 trial, including the global expansion and our continued expansion of our DM-199 clinical development program in preeclampsia. Our general and administrative expenses were $2.5 million and $2.1 million for the three months ended March 31, 2025 and 2024, respectively. This increase resulted primarily from additional non-cash share-based compensation expense recognized as the result of the approval of an extension of the post-termination exercise period for stock options held by a retiring member of our Board of Directors. We expect G&A expenses to remain steady in future periods as compared to recent prior periods. Our net other income was $443,000 for the three months ended March 31, 2025, compared to $597,000 for the three months ended March 31, 2024. This decrease was driven by reduced interest income recognized during the current year period related to lower average marketable securities balances during the current year period as compared to the prior year period. With that, let me ask the operator to open the lines for questions.